Publication: Automated Implantation of Artificial Mitral Chords: Preliminary Results from Feasibility Trial

April 1, 2020

Radolfzell, April 1, 2020: CoreMedic GmbH announces publication of the results of a successful first-in-man trial of its mitral valve chordal repair system ChordArt.

Purpose of the Study

A novel chordal system enables automated implantation of artificial mitral chords to treat mitral regurgitation (MR). This article summarizes the first-in-man initial clinical results.

Description

The CHAGALL (CHordArt system study for the treatment of mitral reGurgitAtion due to leaflet proLapse or fLail) trial is a single arm, multicenter, prospective study to test the feasibility of this system for mitral repair. The interim clinical and echocardiographic results of the first 5 patients with a 12-month follow-up are presented.

Evaluation

Five patients (mean age, 64 years) with severe MR received implantation of neochords with this device under cardiopulmonary bypass. Technical success was obtained in all patients. Transesophageal echocardiogram showed either no or trace residual MR (<1+/4+) after repair. Survival at 30 days was 100%, and no device-related complication occurred. Reduction of MR was sustained up to 12 months.

Conclusions

This novel chordal system is promising because it greatly facilitates the deployment of neochords to repair the mitral valve. Results at 12 months are encouraging. The device is currently under development for transcatheter approach.

Full text publication: https://www.annalsthoracicsurgery.org/article/S0003-4975(19)31425-0/fulltext